A Phase 3 interventional study of 13-valent pneumococcal conjugate vaccine (13vPnC) and diphtheria, tetanus, and acellular pertussis vaccine (DTaP) in Healthy Subjects, sponsored by Pfizer. Completed at 32 sites in Japan. Open to participants aged 3 Months to 6 Months. Per ClinicalTrials.gov, last updated 2018-12-19.
Sponsored by Pfizer · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Subjects will be randomly assigned to 1 of 3 groups to receive the following vaccines: Group 1: 13-valent pneumococcal conjugate vaccine (13vPnC) and diphtheria, tetanus, and acellular pertussis vaccine (DTaP), Group 2: 7-valent pneumococcal conjugate vaccine (7vPnC) and DTaP, Group 3: DTaP alone. Group 3 subjects will also receive catch-up doses of Prevenar (commercial product of Prevenar in Japan) 13vPnC and 7vPnC will be blinded, and DTaP will be open-label. The main purpose of the study is to determine if the immune responses to 13vPnC are comparable to the immune responses to 7vPnC and if the immune responses to 13vPnC given with DTaP are comparable to those induced by DTaP given alone. In addition, the study aims to evaluate the side effects (safety profile) after vaccination of 13vPnC and 7vPnC when given with DTaP in healthy Japanese infants.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Experimental
Biological: 13-valent pneumococcal conjugate vaccine (13vPnC) · Biological: diphtheria, tetanus, and acellular pertussis vaccine (DTaP)
Active comparator
Biological: 7-valent pneumococcal conjugate vaccine (7vPnC) · Biological: DTaP
Active comparator
Biological: DTaP
0.5 mL per dose, 4 doses
0.5 mL per dose, 4 doses
0.5 mL per dose, 4 doses
0.5 mL per dose, 4 doses
0.5 mL per dose, 4 doses
Percentage of Participants Achieving Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Level Greater Than or Equal to (>=) 0.35 Microgram Per Milliliter (mcg/mL) 1 Month After the Infant Series
Percentage of participants achieving predefined antibody threshold \>=0.35 mcg/mL along with the corresponding 95% confidence interval (CI) for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants. To demonstrate non-inferiority, for 6 additional serotypes in 7vPnC + DTaP group, the lowest response observed among the 7 common serotypes in the group was taken as reference.
Time frame: 1 month after the infant series
Geometric Mean Concentration (GMC) of Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody for 7 Common Serotypes 1 Month After the Infant Series
Antibody geometric mean concentration (GMC) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) are presented. GMC (13vPnC) and corresponding 2-sided 95% confidence intervals (CI) were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw.
Time frame: 1 month after the infant series
Percentage of Participants Achieving Predefined Antibody Levels for Diphtheria Toxoid, Tetanus Toxoid, and Pertussis Antigens 1 Month After the Infant Series
Predefined antibody levels were 0.1 International Units/mL (IU/mL) for diphtheria, 0.01 IU/mL for tetanus, 5 Enzyme-linked Immunosorbent Assay (ELISA) units/mL (EU/mL) for pertussis toxoid (PT), and 5 EU/mL for filamentous hemagglutinin (FHA).
Time frame: 1 month after the infant series
Geometric Mean Concentration (GMC) of Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody for 6 Additional Serotypes 1 Month After the Infant Series
Antibody GMC for 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. GMs were calculated using all participants with available data for the specified blood draw. To demonstrate non-inferiority, for 6 additional serotypes in 7vPnC + DTaP group, the lowest GMC observed among the 7 common serotypes in the group was taken as reference.
Time frame: 1 month after the infant series
Percentage of Participants Achieving Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Level >=0.35 mcg/mL 1 Month After the Toddler Dose
Percentage of participants achieving predefined antibody threshold \>=0.35 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants. To demonstrate non-inferiority, for 6 additional serotypes in 7vPnC + DTaP group, the lowest response observed among the 7 common serotypes in the group was taken as reference.
Time frame: 1 month after the toddler dose
Geometric Mean Concentration (GMC) of Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After the Toddler Dose
Antibody GMC as measured by mcg/mL for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% confidence intervals (CI) were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw. To demonstrate non-inferiority, for 6 additional serotypes in 7vPnC + DTaP group, the lowest GMC observed among the 7 common serotypes in the group was taken as reference.
Time frame: 1 month after the toddler dose
Percentage of Participants Achieving Predefined Antibody Levels for Diphtheria Toxoid, Tetanus Toxoid, and Pertussis Antigens 1 Month After the Toddler Dose
Predefined antibody level was 0.1 IU/mL for diphtheria, 0.01 IU/mL for tetanus, 5 EU/mL for PT, and 5 EU/mL for FHA.
Time frame: 1 month after the toddler dose
Geometric Mean Concentration (GMC) for Antigen-specific Diphtheria and Tetanus Antibodies 1 Month After the Infant Series
GMC was measured in IU/mL and corresponding 2-sided 95% CI were evaluated for diphtheria and tetanus antibodies.
Time frame: 1 month after the infant series
Geometric Mean Concentration (GMC) for Antigen-specific Acellular Pertussis Antibodies 1 Month After the Infant Series
GMC was measured in EU/mL and corresponding 2-sided 95% CI were evaluated for PT and FHA antibodies.
Time frame: 1 month after the infant series
Geometric Mean Concentration (GMC) for Antigen-specific Diphtheria and Tetanus Antibody 1 Month After the Toddler Dose
GMC was measured in IU/mL and corresponding 2-sided 95% CI were evaluated for diphtheria and tetanus antibodies.
Time frame: 1 month after the toddler dose
Geometric Mean Concentration (GMC) for Antigen-specific Acellular Pertussis Antibody 1 Month After the Toddler Dose
GMC was measured in EU/mL and corresponding 2-sided 95% CI were evaluated for PT and FHA antibodies.
Time frame: 1 month after the toddler dose
Percentage of Participants Reporting Pre-Specified Local Reactions: Infant Series Dose 1 (3 to 6 Months of Age)
Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.
Time frame: Within 7 days after Dose 1 of the infant series
Percentage of Participants Reporting Pre-Specified Local Reactions: Infant Series Dose 2 (4 to 8 Months of Age)
Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.
Time frame: Within 7 days after Dose 2 of the infant series
Percentage of Participants Reporting Pre-Specified Local Reactions: Infant Series Dose 3 (5 to 10 Months of Age)
Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.
Time frame: Within 7 days after Dose 3 of the infant series
Percentage of Participants Reporting Pre-Specified Local Reactions: Toddler Dose (12 to 15 Months of Age)
Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.
Time frame: Within 7 days after the toddler dose
Percentage of Participants Reporting Pre-Specified Systemic Events: Infant Series Dose 1 (3 to 6 Months of Age)
Systemic events (any fever \>= 37.5 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, decreased sleep, and hives \[urticaria\]) were reported using an electronic diary. Participants may be represented in more than 1 category.
Time frame: Within 7 days after Dose 1 of infant series
Percentage of Participants Reporting Pre-Specified Systemic Events: Infant Series Dose 2 (4 to 8 Months of Age)
Systemic events (any fever \>= 37.5 degrees C, decreased appetite, irritability, increased sleep, decreased sleep, and hives \[urticaria\]) were reported using an electronic diary. Participants may be represented in more than 1 category.
Time frame: Within 7 days after Dose 2 of infant series
Percentage of Participants Reporting Pre-Specified Systemic Events: Infant Series Dose 3 (5 to 10 Months of Age)
Systemic events (any fever \>= 37.5 degrees C, decreased appetite, irritability, increased sleep, decreased sleep, and hives \[urticaria\]) were reported using an electronic diary. Participants may be represented in more than 1 category.
Time frame: Within 7 days after Dose 3 of infant series
Percentage of Participants Reporting Pre-Specified Systemic Events: Toddler Dose (12 to 15 Months of Age)
Systemic events (any fever \>= 37.5 degrees C, decreased appetite, irritability, increased sleep, decreased sleep, and hives \[urticaria\]) were reported using an electronic diary. Participants may be represented in more than 1 category.
Time frame: Within 7 days after the toddler dose
| Milestone | 13vPnC + DTaP | 7vPnC + DTaP | DTaP (Catch-up 7vPnC) |
|---|---|---|---|
| Started | 183 | 184 | 184 |
| Vaccinated dose 1 | 183 | 183 | 183 |
| Vaccinated dose 2 | 183 | 182 | 183 |
| Vaccinated dose 3 | 181 | 178 | 182 |
| Completed | 180 | 178 | 178 |
| Not completed | 3 | 6 | 6 |
| Withdrew: Adverse event | 2 | 2 | 3 |
| Withdrew: Withdrawal by subject | 0 | 2 | 2 |
| Withdrew: Did not meet entrance criteria | 0 | 1 | 0 |
| Withdrew: Randomized, not vaccinated | 0 | 1 | 1 |
| Withdrew: Other | 1 | 0 | 0 |
| Milestone | 13vPnC + DTaP | 7vPnC + DTaP | DTaP (Catch-up 7vPnC) |
|---|---|---|---|
| Started | 180 | 178 | 178 |
| Completed | 162 | 162 | 169 |
| Not completed | 18 | 16 | 9 |
| Withdrew: Adverse event | 6 | 6 | 3 |
| Withdrew: Withdrawal by subject | 10 | 8 | 4 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
| Withdrew: Other | 1 | 2 | 2 |
| Milestone | 13vPnC + DTaP | 7vPnC + DTaP | DTaP (Catch-up 7vPnC) |
|---|---|---|---|
| Started | 162 | 162 | 169 |
| Completed | 162 | 159 | 168 |
| Not completed | 0 | 3 | 1 |
| Withdrew: Adverse event | 0 | 3 | 1 |
Percentage of participants achieving predefined antibody threshold \>=0.35 mcg/mL along with the corresponding 95% confidence interval (CI) for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants. To demonstrate non-inferiority, for 6 additional serotypes in 7vPnC + DTaP group, the lowest response observed among the 7 common serotypes in the group was taken as reference.
| percentage of participants | 13vPnC + DTaP | 7vPnC + DTaP |
|---|---|---|
| 4 | 100.0 (97.9 to 100.0) | 100.0 (97.9 to 100.0) |
| 6B | 97.7 (94.3 to 99.4) | 99.4 (96.9 to 100.0) |
| 9V | 100.0 (97.9 to 100.0) | 100.0 (97.9 to 100.0) |
| 14 | 100.0 (97.9 to 100.0) | 100.0 (97.9 to 100.0) |
| 18C | 100.0 (97.9 to 100.0) | 100.0 (97.9 to 100.0) |
| 19F | 98.9 (96.0 to 99.9) | 96.6 (92.7 to 98.7) |
| 23F | 97.7 (94.3 to 99.4) | 98.3 (95.1 to 99.6) |
| 1 | 100.0 (97.9 to 100.0) | 96.6 (92.7 to 98.7) |
| 3 | 99.4 (96.9 to 100.0) | 96.6 (92.7 to 98.7) |
| 5 | 99.4 (96.9 to 100.0) | 96.6 (92.7 to 98.7) |
| 6A | 98.3 (95.1 to 99.6) | 96.6 (92.7 to 98.7) |
| 7F | 100.0 (97.9 to 100.0) | 96.6 (92.7 to 98.7) |
| 19A | 100.0 (97.9 to 100.0) | 96.6 (92.7 to 98.7) |
Antibody geometric mean concentration (GMC) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) are presented. GMC (13vPnC) and corresponding 2-sided 95% confidence intervals (CI) were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw.
| mcg/mL | 13vPnC + DTaP | 7vPnC + DTaP |
|---|---|---|
| 4 | 9.40 (8.48 to 10.41) | 11.54 (10.51 to 12.67) |
| 6B | 4.50 (3.90 to 5.21) | 5.71 (4.93 to 6.63) |
| 9V | 5.04 (4.52 to 5.62) | 6.80 (6.15 to 7.52) |
| 14 | 13.86 (12.16 to 15.80) | 16.79 (15.03 to 18.76) |
| 18C | 5.30 (4.75 to 5.91) | 7.26 (6.53 to 8.08) |
| 19F | 7.37 (6.43 to 8.46) | 8.38 (7.17 to 9.80) |
| 23F | 3.64 (3.16 to 4.19) | 4.53 (3.96 to 5.18) |
Predefined antibody levels were 0.1 International Units/mL (IU/mL) for diphtheria, 0.01 IU/mL for tetanus, 5 Enzyme-linked Immunosorbent Assay (ELISA) units/mL (EU/mL) for pertussis toxoid (PT), and 5 EU/mL for filamentous hemagglutinin (FHA).
| percentage of participants | 13vPnC + DTaP | 7vPnC + DTaP | DTaP (Catch-up 7vPnC) |
|---|---|---|---|
| Diphtheria | 99.4 (96.9 to 100.0) | 96.6 (92.7 to 98.7) | 100.0 (97.9 to 100.0) |
| Tetanus | 100.0 (97.9 to 100.0) | 100.0 (97.9 to 100.0) | 100.0 (97.9 to 100.0) |
| Pertussis toxoid (PT) | 99.4 (96.9 to 100.0) | 96.6 (92.7 to 98.7) | 100.0 (97.9 to 100.0) |
| Filamentous hemagglutinin (FHA) | 99.4 (96.9 to 100.0) | 96.6 (92.7 to 98.7) | 100.0 (97.9 to 100.0) |
Antibody GMC for 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. GMs were calculated using all participants with available data for the specified blood draw. To demonstrate non-inferiority, for 6 additional serotypes in 7vPnC + DTaP group, the lowest GMC observed among the 7 common serotypes in the group was taken as reference.
| mcg/mL | 13vPnC + DTaP | 7vPnC + DTaP |
|---|---|---|
| 1 | 8.14 (7.23 to 9.18) | 4.53 (3.96 to 5.18) |
| 3 | 4.90 (4.43 to 5.42) | 4.53 (3.96 to 5.18) |
| 5 | 4.64 (4.14 to 5.20) | 4.53 (3.96 to 5.18) |
| 6A | 4.71 (4.15 to 5.34) | 4.53 (3.96 to 5.18) |
| 7F | 8.26 (7.45 to 9.17) | 4.53 (3.96 to 5.18) |
| 19A | 8.56 (7.67 to 9.56) | 4.53 (3.96 to 5.18) |
Percentage of participants achieving predefined antibody threshold \>=0.35 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants. To demonstrate non-inferiority, for 6 additional serotypes in 7vPnC + DTaP group, the lowest response observed among the 7 common serotypes in the group was taken as reference.
| percentage of participants | 13vPnC + DTaP | 7vPnC + DTaP |
|---|---|---|
| 4 | 100.0 (97.7 to 100.0) | 100.0 (97.6 to 100.0) |
| 6B | 100.0 (97.7 to 100.0) | 100.0 (97.6 to 100.0) |
| 9V | 100.0 (97.7 to 100.0) | 100.0 (97.6 to 100.0) |
| 14 | 100.0 (97.7 to 100.0) | 100.0 (97.6 to 100.0) |
| 18C | 100.0 (97.7 to 100.0) | 100.0 (97.6 to 100.0) |
| 19F | 98.7 (95.5 to 99.8) | 99.4 (96.4 to 100.0) |
| 23F | 100.0 (97.7 to 100.0) | 100.0 (97.6 to 100.0) |
| 1 | 99.4 (96.5 to 100.0) | 99.4 (96.4 to 100.0) |
| 3 | 99.4 (96.5 to 100.0) | 99.4 (96.4 to 100.0) |
| 5 | 100.0 (97.7 to 100.0) | 99.4 (96.4 to 100.0) |
| 6A | 100.0 (97.7 to 100.0) | 99.4 (96.4 to 100.0) |
| 7F | 100.0 (97.7 to 100.0) | 99.4 (96.4 to 100.0) |
| 19A | 100.0 (97.7 to 100.0) | 99.4 (96.4 to 100.0) |
Antibody GMC as measured by mcg/mL for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% confidence intervals (CI) were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw. To demonstrate non-inferiority, for 6 additional serotypes in 7vPnC + DTaP group, the lowest GMC observed among the 7 common serotypes in the group was taken as reference.
| mcg/mL | 13vPnC + DTaP | 7vPnC + DTaP |
|---|---|---|
| 4 | 15.34 (13.23 to 17.79) | 16.35 (14.19 to 18.83) |
| 6B | 17.05 (14.47 to 20.08) | 13.91 (11.93 to 16.21) |
| 9V | 7.00 (6.11 to 8.03) | 8.64 (7.54 to 9.89) |
| 14 | 19.70 (17.69 to 21.93) | 20.69 (18.25 to 23.47) |
| 18C | 8.10 (6.94 to 9.47) | 9.88 (8.64 to 11.30) |
| 19F | 16.73 (14.20 to 19.71) | 9.55 (8.11 to 11.26) |
| 23F | 8.64 (7.46 to 10.01) | 10.00 (8.61 to 11.62) |
| 1 | 13.96 (11.94 to 16.31) | 8.64 (7.54 to 9.89) |
| 3 | 2.48 (2.17 to 2.85) | 8.64 (7.54 to 9.89) |
| 5 | 11.10 (9.83 to 12.53) | 8.64 (7.54 to 9.89) |
| 6A | 15.17 (13.31 to 17.30) | 8.64 (7.54 to 9.89) |
| 7F | 10.90 (9.54 to 12.45) | 8.64 (7.54 to 9.89) |
| 19A | 16.02 (14.07 to 18.25) | 8.64 (7.54 to 9.89) |
Predefined antibody level was 0.1 IU/mL for diphtheria, 0.01 IU/mL for tetanus, 5 EU/mL for PT, and 5 EU/mL for FHA.
| percentage of participants | 13vPnC + DTaP | 7vPnC + DTaP | DTaP (Catch-up 7vPnC) |
|---|---|---|---|
| Diphtheria | 100.0 (97.7 to 100.0) | 100.0 (97.6 to 100.0) | 100.0 (97.8 to 100.0) |
| Tetanus | 100.0 (97.7 to 100.0) | 100.0 (97.6 to 100.0) | 100.0 (97.8 to 100.0) |
| Pertussis toxoid (PT) | 100.0 (97.7 to 100.0) | 100.0 (97.6 to 100.0) | 100.0 (97.8 to 100.0) |
| Filamentous hemagglutinin (FHA) | 100.0 (97.7 to 100.0) | 100.0 (97.6 to 100.0) | 100.0 (97.8 to 100.0) |
GMC was measured in IU/mL and corresponding 2-sided 95% CI were evaluated for diphtheria and tetanus antibodies.
| IU/mL | 13vPnC + DTaP | 7vPnC + DTaP | DTaP (Catch-up 7vPnC) |
|---|---|---|---|
| Diphtheria | 1.03 (0.94 to 1.12) | 1.10 (0.97 to 1.25) | 0.93 (0.86 to 1.02) |
| Tetanus | 1.50 (1.31 to 1.70) | 1.37 (1.17 to 1.60) | 1.66 (1.50 to 1.83) |
GMC was measured in EU/mL and corresponding 2-sided 95% CI were evaluated for PT and FHA antibodies.
| EU/mL | 13vPnC + DTaP | 7vPnC + DTaP | DTaP (Catch-up 7vPnC) |
|---|---|---|---|
| Pertussis toxoid (PT) | 66.12 (60.45 to 72.32) | 57.26 (49.23 to 66.60) | 67.64 (62.87 to 72.78) |
| Filamentous hemagglutinin (FHA) | 62.30 (56.59 to 68.59) | 53.86 (47.27 to 61.37) | 67.48 (61.64 to 73.86) |
GMC was measured in IU/mL and corresponding 2-sided 95% CI were evaluated for diphtheria and tetanus antibodies.
| IU/mL | 13vPnC + DTaP | 7vPnC + DTaP | DTaP (Catch-up 7vPnC) |
|---|---|---|---|
| Diphtheria | 2.65 (2.43 to 2.90) | 3.18 (2.94 to 3.45) | 2.63 (2.39 to 2.91) |
| Tetanus | 2.90 (2.56 to 3.28) | 2.60 (2.29 to 2.95) | 2.89 (2.58 to 3.25) |
GMC was measured in EU/mL and corresponding 2-sided 95% CI were evaluated for PT and FHA antibodies.
| EU/mL | 13vPnC + DTaP | 7vPnC + DTaP | DTaP (Catch-up 7vPnC) |
|---|---|---|---|
| Pertussis toxoid (PT) | 144.46 (130.68 to 159.68) | 135.65 (124.16 to 148.21) | 150.21 (136.20 to 165.65) |
| Filamentous hemagglutinin (FHA) | 143.68 (130.94 to 157.66) | 141.19 (129.20 to 154.30) | 180.31 (163.12 to 199.32) |
Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.
| percentage of participants | 13vPnC + DTaP | 7vPnC + DTaP | DTaP (Catch-up 7vPnC) |
|---|---|---|---|
| Redness- Any (n=171, 172, 165) | 58.5 | 55.8 | 10.3 |
| Redness- Mild (n=170, 172, 165) | 48.2 | 51.2 | 10.3 |
| Redness- Moderate (n=164, 166, 162) | 18.9 | 18.1 | 0.0 |
| Redness- Severe (n=161, 162, 162) | 0.0 | 0.6 | 0.0 |
| Swelling- Any (n=168, 168, 164) | 41.1 | 35.7 | 4.9 |
| Swelling- Mild (n= 168, 168, 164) | 38.1 | 31.5 | 4.9 |
| Swelling- Moderate (n=162, 165, 162) | 12.3 | 12.7 | 0.0 |
| Swelling- severe (n=161, 162, 162) | 0.0 | 0.6 | 0.0 |
| Tenderness- Any (n=163, 164, 162) | 13.5 | 6.1 | 1.2 |
| Tenderness- Significant (n=161, 162, 162) | 0.0 | 0.0 | 0.0 |
| Any local reaction (n=175, 174, 165) | 68.0 | 60.9 | 12.1 |
Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.
| percentage of participants | 13vPnC + DTaP | 7vPnC + DTaP | DTaP (Catch-up 7vPnC) |
|---|---|---|---|
| Redness- Any (n= 166, 168, 161) | 62.7 | 61.9 | 36.6 |
| Redness- Mild (n= 166, 167, 161) | 56.0 | 56.9 | 34.8 |
| Redness- Moderate (n= 157, 159, 156) | 26.1 | 27.0 | 8.3 |
| Redness- Severe (n= 157, 154, 154) | 0.0 | 0.0 | 0.0 |
| Swelling- Any (n= 160, 171, 162) | 48.1 | 50.9 | 24.1 |
| Swelling- Mild (n= 160, 170, 162) | 44.4 | 48.2 | 22.8 |
| Swelling- Moderate (n= 157, 157, 155) | 19.7 | 17.8 | 5.8 |
| Swelling- severe (n= 157, 154, 154) | 0.0 | 0.0 | 0.0 |
| Tenderness- Any (n= 159, 154, 155) | 14.5 | 4.5 | 1.9 |
| Tenderness- Significant (n= 157, 154, 154) | 0.6 | 0.0 | 0.0 |
| Any local reaction (n=167, 173, 164) | 71.3 | 67.1 | 40.2 |
Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.
| percentage of participants | 13vPnC + DTaP | 7vPnC + DTaP | DTaP (Catch-up 7vPnC) |
|---|---|---|---|
| Redness- Any (n= 168, 162, 156) | 53.6 | 51.2 | 23.1 |
| Redness- Mild (n= 167, 160, 156) | 47.3 | 43.1 | 21.8 |
| Redness- Moderate (n= 152, 154, 153) | 17.1 | 22.1 | 2.0 |
| Redness- Severe (n= 149, 152, 152) | 0.0 | 0.0 | 0.0 |
| Swelling- Any (n= 164, 157, 159) | 43.9 | 37.6 | 21.4 |
| Swelling- Mild (n= 164, 156, 159) | 42.1 | 34.0 | 20.1 |
| Swelling- Moderate (n= 150, 154, 153) | 10.7 | 14.9 | 2.6 |
| Swelling- severe (n= 149, 152, 152) | 0.0 | 0.0 | 0.0 |
| Tenderness- Any (n= 153, 155, 153) | 7.8 | 7.1 | 2.6 |
| Tenderness- Significant (n= 149, 152, 152) | 0.0 | 0.0 | 0.7 |
| Any local reaction (n=171, 163, 160) | 62.0 | 55.8 | 28.8 |
Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.
| percentage of participants | 13vPnC + DTaP | 7vPnC + DTaP | DTaP (Catch-up 7vPnC) |
|---|---|---|---|
| Redness- Any (n= 148, 152, 149) | 62.2 | 57.2 | 34.9 |
| Redness- Mild (n= 148, 151, 148) | 50.0 | 47.7 | 28.4 |
| Redness- Moderate (n= 141, 139, 145) | 27.7 | 27.3 | 13.1 |
| Redness- Severe (n= 140, 136, 141) | 0.0 | 0.0 | 0.0 |
| Swelling- Any (n= 149, 144, 148) | 49.0 | 45.8 | 26.4 |
| Swelling- Mild (n= 147, 143, 146) | 42.9 | 42.0 | 22.6 |
| Swelling- Moderate (n= 143, 138, 146) | 16.8 | 18.8 | 13.0 |
| Swelling- severe (n= 140, 136, 141) | 0.0 | 0.0 | 0.0 |
| Tenderness- Any (n= 142, 140 ,142) | 14.1 | 10.0 | 5.6 |
| Tenderness- Significant (n= 140, 136, 141) | 0.7 | 0.0 | 0.0 |
| Any local reaction (n=153, 152, 151) | 68.6 | 61.8 | 37.1 |
Systemic events (any fever \>= 37.5 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, decreased sleep, and hives \[urticaria\]) were reported using an electronic diary. Participants may be represented in more than 1 category.
| percentage of participants | 13vPnC + DTaP | 7vPnC + DTaP | DTaP (Catch-up 7vPnC) |
|---|---|---|---|
| Fever >=37.5,=<39 degrees C (n=168, 168, 165) | 36.3 | 33.9 | 21.8 |
| Fever >39,=<40 degrees C (n=161, 163, 162) | 0.6 | 1.2 | 0.6 |
| Fever >40 degrees C (n=161, 162, 162) | 0.0 | 0.0 | 0.0 |
| Decreased appetite (n=163, 163, 165) | 12.9 | 9.2 | 7.3 |
| Irritability (n=165, 164, 164) | 18.8 | 16.5 | 12.2 |
| Increased sleep (n=170, 165, 165) | 28.8 | 26.7 | 21.8 |
| Decreased sleep (n=164, 169, 167) | 18.3 | 21.3 | 13.8 |
| Hives- urticaria (n=161, 162, 162) | 3.1 | 1.2 | 0.0 |
| Use of antipyretic medication (n= 161, 162, 162) | 3.7 | 2.5 | 0.6 |
| Any systemic event (n=177, 174, 172) | 61.0 | 59.8 | 43.0 |
Systemic events (any fever \>= 37.5 degrees C, decreased appetite, irritability, increased sleep, decreased sleep, and hives \[urticaria\]) were reported using an electronic diary. Participants may be represented in more than 1 category.
| percentage of participants | 13vPnC + DTaP | 7vPnC + DTaP | DTaP (Catch-up 7vPnC) |
|---|---|---|---|
| Fever >=37.5, =<39 degrees C (n=166, 161, 155) | 36.7 | 36.6 | 21.9 |
| Fever >39, =<40 degrees C (n=158, 155, 154) | 1.9 | 3.9 | 0.6 |
| Fever >40 degrees C (n=157, 154, 154) | 0.0 | 0.0 | 0.0 |
| Decreased appetite (n=158, 159, 155) | 11.4 | 14.5 | 7.1 |
| Irritability (n=162, 155, 156) | 17.9 | 18.7 | 10.9 |
| Increased sleep (n=163, 158, 163) | 22.7 | 22.2 | 22.7 |
| Decreased sleep (n=161, 157, 157) | 18.6 | 12.1 | 12.1 |
| Hives- urticaria (n=157, 154, 154) | 2.5 | 1.3 | 1.9 |
| Use of antipyretic medication (n=160, 155, 154) | 3.1 | 4.5 | 1.3 |
| Any systemic event (n=170, 169, 166) | 61.2 | 57.4 | 44.6 |
Systemic events (any fever \>= 37.5 degrees C, decreased appetite, irritability, increased sleep, decreased sleep, and hives \[urticaria\]) were reported using an electronic diary. Participants may be represented in more than 1 category.
| percentage of participants | 13vPnC + DTaP | 7vPnC + DTaP | DTaP (Catch-up 7vPnC) |
|---|---|---|---|
| Fever >=37.5, =<39 degrees C (n=162, 161, 157) | 34.6 | 30.4 | 24.2 |
| Fever >39, =<40 degrees C (n=150, 152, 153) | 3.3 | 2.0 | 3.3 |
| Fever >40 degrees C (n=149, 152, 152) | 0.0 | 0.7 | 0.0 |
| Decreased appetite (n=152, 155, 154) | 9.9 | 9.7 | 5.8 |
| Irritability (n=154, 156, 154) | 17.5 | 14.7 | 11.7 |
| Increased sleep (n=151, 157, 154) | 20.5 | 20.4 | 14.9 |
| Decreased sleep (n= 154, 156, 153) | 18.2 | 12.8 | 9.8 |
| Hives- urticaria (n= 149, 152, 152) | 1.3 | 0.0 | 1.3 |
| Use of antipyretic medication (n=150, 153, 154) | 2.0 | 3.3 | 4.5 |
| Any systemic event (n=168, 164, 159) | 57.7 | 50.0 | 40.9 |
Systemic events (any fever \>= 37.5 degrees C, decreased appetite, irritability, increased sleep, decreased sleep, and hives \[urticaria\]) were reported using an electronic diary. Participants may be represented in more than 1 category.
| percentage of participants | 13vPnC + DTaP | 7vPnC + DTaP | DTaP (Catch-up 7vPnC) |
|---|---|---|---|
| Fever >=37.5, =<39 degrees C (n=145, 146, 146) | 49.0 | 49.3 | 31.5 |
| Fever >39, =<40 degrees C (n=141, 136, 141) | 4.3 | 8.8 | 3.5 |
| Fever >40 degrees C (n=139, 137, 141) | 1.4 | 2.2 | 0.0 |
| Decreased appetite (n=143, 141, 143) | 19.6 | 19.9 | 9.8 |
| Irritability (n=143, 141, 144) | 18.2 | 21.3 | 16.7 |
| Increased sleep (n=145, 142, 143) | 18.6 | 17.6 | 16.1 |
| Decreased sleep (n=142, 137, 141) | 12.7 | 9.5 | 11.3 |
| Hives- urticaria (n=140, 136, 141) | 3.6 | 2.2 | 2.1 |
| Use of antipyretic medication (n=141, 138, 142) | 7.1 | 9.4 | 4.2 |
| Any systemic event (n=148, 152, 149) | 62.8 | 63.8 | 50.3 |
Collected over AEs/SAEs: recorded from signing of informed consent form to completion of study. Participants recorded pre-specified AEs in electronic diary:local reactions; systemic events; use of antipyretic medication (up to 7 days after each vaccine dose).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 13vPnC + DTaP - Infant Series | — | 5/183 (2.7%) | 147/183 (80.3%) |
| 7vPnC + DTaP - Infant Series | — | 8/183 (4.4%) | 160/183 (87.4%) |
| DTaP (Catch-up 7vPnC) - Infant Series | — | 10/183 (5.5%) | 155/183 (84.7%) |
| 13vPnC + DTaP - After the Infant Series | — | 13/183 (7.1%) | 20/183 (10.9%) |
| 7vPnC + DTaP - After the Infant Series | — | 15/183 (8.2%) | 27/183 (14.8%) |
| DTaP (Catch-up 7vPnC) - After the Infant Series | — | 10/183 (5.5%) | 147/183 (80.3%) |
| 13vPnC + DTaP - Toddler Dose | — | 0/162 (0%) | 104/162 (64.2%) |
| 7vPnC + DTaP - Toddler Dose | — | 4/162 (2.5%) | 99/162 (61.1%) |
| DTaP (Catch-up 7vPnC) - Toddler Dose | — | 2/169 (1.2%) | 112/169 (66.3%) |
| DTaP (Catch-up 7vPnC) - After the Toddler Dose | — | 2/169 (1.2%) | 105/169 (62.1%) |
| Event | 13vPnC + DTaP - Infant Series | 7vPnC + DTaP - Infant Series | DTaP (Catch-up 7vPnC) - Infant Series | 13vPnC + DTaP - After the Infant Series | 7vPnC + DTaP - After the Infant Series | DTaP (Catch-up 7vPnC) - After the Infant Series | 13vPnC + DTaP - Toddler Dose | 7vPnC + DTaP - Toddler Dose | DTaP (Catch-up 7vPnC) - Toddler Dose | DTaP (Catch-up 7vPnC) - After the Toddler Dose |
|---|---|---|---|---|---|---|---|---|---|---|
| Febrile convulsionNervous system disorders | 0/183 | 1/183 | 1/183 | 6/183 | 5/183 | 3/183 | 0/162 | 3/162 | 1/169 | 2/169 |
| GastroenteritisInfections and infestations | 1/183 | 1/183 | 0/183 | 0/183 | 3/183 | 0/183 | 0/162 | 0/162 | 0/169 | 0/169 |
| PneumoniaInfections and infestations | 1/183 | 0/183 | 0/183 | 0/183 | 0/183 | 3/183 | 0/162 | 1/162 | 0/169 | 0/169 |
| Respiratory syncytial virus bronchiolitisInfections and infestations | 1/183 | 0/183 | 3/183 | 1/183 | 0/183 | 0/183 | 0/162 | 0/162 | 0/169 | 0/169 |
| BronchitisInfections and infestations | 1/183 | 1/183 | 0/183 | 1/183 | 2/183 | 0/183 | 0/162 | 0/162 | 0/169 | 0/169 |
| Pneumonia respiratory syncytial viralInfections and infestations | 0/183 | 0/183 | 2/183 | 0/183 | 0/183 | 0/183 | 0/162 | 0/162 | 0/169 | 0/169 |
| Kawasaki's diseaseVascular disorders | 0/183 | 0/183 | 2/183 | 1/183 | 1/183 | 0/183 | 0/162 | 0/162 | 0/169 | 0/169 |
| Gastroenteritis rotavirusInfections and infestations | 0/183 | 0/183 | 0/183 | 0/183 | 2/183 | 1/183 | 0/162 | 0/162 | 0/169 | 0/169 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/183 | 0/183 | 0/183 | 1/183 | 0/183 | 1/183 | 0/162 | 1/162 | 0/169 | 0/169 |
| Respiratory syncytial virus infectionInfections and infestations | 0/183 | 0/183 | 0/183 | 0/183 | 0/183 | 0/183 | 0/162 | 0/162 | 1/169 | 0/169 |
| Event | 13vPnC + DTaP - Infant Series | 7vPnC + DTaP - Infant Series | DTaP (Catch-up 7vPnC) - Infant Series | 13vPnC + DTaP - After the Infant Series | 7vPnC + DTaP - After the Infant Series | DTaP (Catch-up 7vPnC) - After the Infant Series | 13vPnC + DTaP - Toddler Dose | 7vPnC + DTaP - Toddler Dose | DTaP (Catch-up 7vPnC) - Toddler Dose | DTaP (Catch-up 7vPnC) - After the Toddler Dose |
|---|---|---|---|---|---|---|---|---|---|---|
| Redness (Any)Skin and subcutaneous tissue disorders | 104/166 | 104/168 | 59/161 | — | — | — | — | — | — | — |
| Redness (Any)Skin and subcutaneous tissue disorders | 100/171 | 96/172 | 17/165 | — | — | — | 92/148 | 87/152 | 52/149 | — |
| Redness (Mild)Skin and subcutaneous tissue disorders | 93/166 | 95/167 | 56/161 | — | — | — | — | — | — | — |
| Redness (Any)Skin and subcutaneous tissue disorders | 90/168 | 83/162 | 36/156 | — | — | — | — | — | — | — |
| Redness (Mild)Skin and subcutaneous tissue disorders | 82/170 | 88/172 | 17/165 | — | — | — | 74/148 | 72/151 | 42/148 | — |
| Swelling (Any)Skin and subcutaneous tissue disorders | 77/160 | 87/171 | 39/162 | — | — | — | — | — | — | — |
| Fever >=37.5, =<39 degrees CGeneral disorders | 61/168 | 57/168 | 36/165 | — | — | — | 71/145 | 72/146 | 46/146 | — |
| Swelling (Any)Skin and subcutaneous tissue disorders | 69/168 | 60/168 | 8/164 | — | — | — | 73/149 | 66/144 | 39/148 | — |
| Swelling (Mild)Skin and subcutaneous tissue disorders | 71/160 | 82/170 | 37/162 | — | — | — | — | — | — | — |
| Redness (Mild)Skin and subcutaneous tissue disorders | 79/167 | 69/160 | 34/156 | — | — | — | — | — | — | — |
| Age, Continuous(months) | 13vPnC + DTaP | 7vPnC + DTaP | DTaP (Catch-up 7vPnC) | Total |
|---|---|---|---|---|
| Mean | 4.1 ± 0.97 | 4.1 ± 0.97 | 4.2 ± 0.96 | 4.1 ± 0.97 |
| Sex: Female, Male(Participants) | 13vPnC + DTaP | 7vPnC + DTaP | DTaP (Catch-up 7vPnC) | Total |
|---|---|---|---|---|
| Female | 87 | 91 | 91 | 269 |
| Male | 96 | 93 | 93 | 282 |
Ran from Sep 2010 to primary completion in Nov 2011, 14 months.
Results were first posted in Oct 2012, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 13-valent pneumococcal vaccine